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Abstract
Introduction: As part of the MicroArray Quality Control (MAQC)-II project, this analysis examines how the choice of
univariate feature-selection methods and classification algorithms may influence the performance of genomic
predictors under varying degrees of prediction difficulty represented by three clinically relevant endpoints.
Methods: We used gene-expression data from 230 breast cancers (grouped into training and independent
validation sets), and we examined 40 predictors (five univariate feature-selection methods combined with eight
different classifiers) for each of the three endpoints. Their classification performance was estimated on the training
set by using two different resampling methods and compared with the accuracy observed in the independent
validation set.
Results: A ranking of the three classification problems was obtained, and the performance of 120 models was
estimated and assessed on an independent validation set. The bootstrapping estimates were closer to the
validation performance than were the cross-validation estimates. The required sample size for each endpoint was
estimated, and both gene-level and pathway-level analyses were performed on the obtained models.
Conclusions: We showed that genomic predictor accuracy is determined largely by an interplay between sample
size and classification difficulty. Variations on univariate feature-selection methods and choice of classification
algorithm have only a modest impact on predictor performance, and several statistically equally good predictors
can be developed for any given classification problem.
Introduction
Gene-expression profiling with microarrays represents a
novel tissue analytic tool that has been applied success-
fully to cancer classification, and the first generation of
genomic prognostic signatures for breast cancer is
already on the market [1-3]. So far, most of the pub-
lished literature has addressed relatively simple classifi-
cation problems, including separation of cancer from
normal tissue, distinguishing between different types of
cancers, or sorting cancers into good or bad prognoses
[4]. The transcriptional differences between these condi-
tions or disease states are often large compared with
transcriptional variability within the groups, and there-
fore, reasonably successful classification is possible. The
methodologic limitations and performance characteris-
tics of gene expression based classifiers have not been
examined systematically when applied to increasingly
challenging classification problems in real clinical data
sets.
The MicroArray Quality Control (MAQC) (MAQC
Consortium project-II: a comprehensive study of com-
mon practices for the development and validation of
microarray-based predictive models) breast cancer data
set (Table 1) offers a unique opportunity to study the
performance of genomic classifiers when applied across
a range of classification difficulties.
One of the most important discoveries in breast can-
cer research in recent years has been the realization that
estrogen receptor (ER)-positive and -negative breast can-
cers represent molecularly distinct diseases with large
differences in gene-expression patterns [5,6]. Therefore,
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gene expression-based prediction of ER status represents
an easy classification problem.
A somewhat more difficult problem is to predict
extreme chemotherapy sensitivity, including all breast
cancers in the analysis. This classification problem is
facilitated by the association between clinical disease
characteristics and chemotherapy sensitivity. For exam-
ple, ER-negative cancers are more chemotherapy sensi-
tive than are ER-positive tumors [7].
A third, and more difficult, classification problem is to
predict disease outcome in clinically and molecularly
homogeneous patient populations. Genomic predictors
could have the greatest clinical impact here, because tra-
ditional clinical variables alone are only weakly discrimi-
natory of outcome in these populations. In the current
data set, prediction of chemotherapy sensitivity among
the ER-negative cancers represents such a challenge.
The goal of this analysis was to assess how the
degree of classification difficulty may affect which ele-
ments of prediction methods perform better. We
divided the data into a training set (n = 130) and a
validation set (n = 100) and developed a series of
Table 1 Patient characteristics in the training and validation sets
Training set (n = 130) Validation set (n = 100) P value
Median age 51 years (28-79 years) 50 years (26-73 years)
Race 0.804
Caucasian 85 (65%) 68 (68%)
African American 13 (10%) 12 (12%)
Asian 9 (7%) 7 (7%)
Hispanic 21 (16%) 13 (13%)
Mixed 2 (2%) 0
Cancer histology 0.047
Invasive ductal (IDC) 119 (92%) 85 (85%)
Mixed ductal/lobular (IDC/ILC) 8 (6%) 8 (8%)
Invasive lobular (ILC) 1 (0.7%) 7 (7%)
Others 2 (1.3%) 0
Tumor size 0.643
T0 1 (1%) 2 (2%)
T1 12 (9%) 8 (8%)
T2 70 (54%) 62 (62%)
T3 21 (16%) 13 (13%)
T4 26 (20%) 15 (15%)
Lymph node stage 0.935
N0 39 (30%) 27 (27%)
N1 60 (46%) 47 (47%)
N2 14 (11%) 13 (13%)
N3 17 (13%) 13 (13%)
Nuclear grade (BMN) 0.005
1 2 (2%) 11 (11%)
2 52 (40%) 42 (42%)
3 76 (58%) 47 (47%)
Estrogen receptor 0.813
Estrogen receptor positive 80 (62%) 60 (60%)
Estrogen receptor negative 50 (38%) 40 (40%)
HER-2 < 0.001
HER-2 positive 33 (25%) 7 (7%)
HER-2 negative 96 (74%) 93 (93%)
Neoadjuvant therapy 0.005
Weekly T × 12 + FAC × 4 112 (86%) 98 (98%)
3-Weekly T × 4 + FAC × 4 18 (14%) 2 (2%)
Pathologic complete response (pCR) 33 (25%) 15 (15%) 0.055
Estrogen receptor: cases in which more than 10% of tumor cells stained positive for ER with immunohistochemistry (IHC) were considered positive. HER-2: cases
that showed either 3+ IHC staining or had gene copy number greater than 2.0 were considered HER-2 “positive.” T = paclitaxel; FAC = 5-fluorouracil, doxorubicin,
and cyclophosphamide. The P values for the association tests were obtained from a c2 test unless the number of cases was fewer than five in any category, in
which case, Fisher’s Exact test was used.
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classifiers to predict (a) ER status, (b) pathologic com-
plete response (pCR) to preoperative chemotherapy for
all breast cancers, and (c) pCR for ER-negative breast
cancers. A predictor, or classifier, in this article is
defined as a set of informative features (generated by a
particular feature-selection method) and a trained dis-
crimination rule (produced by applying a particular
classification algorithm).
First, we examined whether the success of a predictor
was influenced by a feature-selection method. We exam-
ined five different univariate feature-selection methods
including three variations of a t test-based ranking and
two methods that order features based on differences in
expression values. It has been shown that several differ-
ent classification algorithms can yield predictors with
rather similar performance metrics [8-10]. However, it
remains unknown whether the relative performances of
different methods may vary depending on the difficulty
of the prediction problem. We examined this question
for eight different classifiers representing a broad range
of algorithms, including linear (LDA), diagonal linear
(DLDA), and quadratic discriminant analysis (QDA);
logistic regression (LREG); and two versions of support-
vector machines (SVM) and k-nearest neighbor (KNN)
methods. Altogether, 40 different predictors were devel-
oped for each of the three classification problems (five
different feature-selection methods × eight different
classifiers). We also were interested determine to what
extent the cross-validation classification performance is
influenced by different data-resampling methods and the
difficulty of the classification problem. We estimated the
classification performance by using 10-times-repeated
fivefold cross validation (10 × 5-CV) and leave-pair-out
(LPO) bootstrapping [11] (a method that better accounts
for training and testing variability). We calculated per-
formance metrics for each of the 120 predictors (40 pre-
dictors × three endpoints) and compared the estimated
accuracy in the training set with the observed accuracy
in the independent validation set.
Materials and methods
Patients and materials
Gene-expression data from 230 stage I to III breast
cancers, without individual patient identifiers, were
provided to the MAQC project by the University of
Texas M.D. Anderson Cancer Center (MDACC) Breast
Cancer Pharmacogenomic Program. Gene-expression
results were generated from fine-needle aspiration spe-
cimens of newly diagnosed breast cancers before any
therapy. The biopsy specimens were collected sequen-
tially during a prospective pharmacogenomic marker
discovery study approved by the institutional review
board between 2000 and 2008. These specimens
represent 70% to 90% pure neoplastic cells with mini-
mal stromal contamination [12]. All patients signed
informed consent for genomic analysis of their cancers.
Patients received 6 months of preoperative (neoadju-
vant) chemotherapy including paclitaxel, 5-fluorouracil,
cyclophosphamide, and doxorubicin, followed by surgi-
cal resection of the cancer. Response to preoperative
chemotherapy was categorized as a pathologic com-
plete response (pCR = no residual invasive cancer in
the breast or lymph nodes) or residual invasive cancer
(RD). The prognostic value of pCR has been discussed
extensively in the medical literature [13]. Genomic
analyses of subsets of this sequentially accrued patient
population were reported previously [9,14,15]. For each
endpoint, we used the first 130 cases as a training set
to develop prediction models, and the next 100 cases
were set aside as independent validation set. Table 1
and Additional file 1 show patient and sample charac-
teristics in the two data sets.
Gene-expression profiling
Needle-aspiration specimens of the cancer were placed
into RNAlater™ solution (Qiagen, Germantown, MD,
USA) and stored at -80°C until further analysis. RNA
extraction and gene-expression profiling were per-
formed in multiple batches over time, as described pre-
viously [16,17] by using Affymetrix U133A (Affymetrix,
Santa Clara, CA, USA) microarrays. Gene-expression
data have been uploaded to the Gene Expression Omni-
bus website under the accession number GSE16716.
Normalization was performed by using MAS 5.0 soft-
ware (Affymetrix, Santa Clara, CA, USA) with default
settings. Quality-control assessment of the hybridization
results were performed with SimpleAffy software by
Bioconductor; the percentage present call had to be
more than 30%, scaling factor less than 3, and the 3’/5’
ratios for b-actin less than 3, and for GAPDH, less than
1.3. These quality-control metrics are presented for
each case in Additional file 2.
Ranking of classification problems by informative feature
utility score
To assess the relative difficulty of the three classification
problems that we selected to study, we adopted an
approach similar to that described in [18]. This method
defines the utility of a feature i as its Fisher score,
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where μ1i and μ2i are the class means, and s1i and s2i
are the class standard deviations for the feature i,
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respectively. If features are ordered f1 ≥ f2 ≥ ... then, for
each endpoint, the cumulative information is defined as
F fj i
i
j N
=
=
≤∑
1
,
where N is the sample size. This cumulative informa-
tion score assumes that the features are independent
and that their effect on the classification performance is
additive. This is rarely the case, as features are often
correlated. Nonetheless, this cumulative information
score is a simple and straightforward approach to esti-
mate the relative difficulty of a classification problem
early in the classifier-development process: an easier
problem tends to have larger values for F than does a
more difficult problem.
Feature-selection methods
No prefiltering of probe sets was done; all probe sets were
considered by the feature-ranking methods that included
(a) unequal variance t test (FS1); (b) unequal variance t
test with filtering of probe sets that were correlated with
one another (Pearson correlation > 0.75) to generate inde-
pendently informative features (FS2); (c) instead of remov-
ing the correlated features, they were combined into meta-
features by averaging them (FS3); and (d) we also ranked
features according to their ratio of between- to within-
group sum of squares (FS4) and (e) according to the abso-
lute differences in the class means (FS5).
Classification algorithms
We examined eight classifiers in combination with the
previously mentioned feature-selection methods, includ-
ing linear discriminant analysis (LDA), diagonal linear
discriminant analysis (DLDA), quadratic discriminant
analysis (QDA), logistic regression (LREG), two k near-
est neighbors classifiers with k = 3 (KNN3) and k = 11
(KNN11), and support vector machines with a radial
basis function kernel with two different values for the
kernel parameter: g = 0.5 (SVM05) and g = 2.0 (SVM2),
respectively. Overall, 40 models were developed for each
of the three prediction problems.
Estimation of predictive performance
Leave-N-out cross-validation and other resampling
methods of the training set are often used to select a
final predictor for independent validation. Therefore, it
is important to understand how resampling-based pre-
dictive performance correlates with predictive perfor-
mance on independent validation cases. To study this
question, we used a nested two-level cross-validation
scheme, in which the cross-validation in the outer loop
had the role of estimating the performance of the whole
modeling procedure, whereas the cross-validation in the
inner loop was used for selecting the optimal number of
features [19].
The procedure in the inner loop is as follows. For
each combination of a feature-selection method F and
a classification algorithm C, the number of features j
(F, C) in the model was considered as a free-parameter
(within a predefined set of allowable values) and was
optimized. In the inner loop, a repeated (5 times), stra-
tified (to preserve the proportion of the two classes in
all training and testing splits), fivefold cross-validation
was used to define the number of features that maxi-
mized the AUC. A ranking of the features was first
obtained by applying F on the reduced internal train-
ing set (obtained by leaving aside one fold from the
current training set). Then the classifier C was trained
on the same set, but considering only the top j(F, C)
features. The predictions on the internal testing set
(the left-out fold) were recorded, and the procedure
was repeated. At the end, an estimation of the AUC
was obtained, corresponding to the given combination
of F, C, and j(F, C). The procedure was repeated with
different folds, and an average estimate of the AUC
was obtained for each F, C, and j(F, C). The optimal
number of features j*(F, C) was selected as the value j
(F, C) yielding the highest average AUC. The number
of features allowed for each model was chosen a
priori, to avoid overfitting of models and to limit the
computation time. For the prediction of ER status, the
feature size was chosen to contain all values between 2
and 15, whereas for both pCR endpoints, it was
{2,5,8,...,41}; 41 being almost half the size of the smal-
lest training set (n = 85 ER-negative cancer). For a
pseudo-code that details the schema used for cross-
validation [see Additional file 3]. To avoid adding
variability due to random partitioning the data into
folds, all estimates were obtained on the same splits of
the data.
We investigated two methods in the outer loop. The
first method is a stratified 10-times-repeated fivefold
cross-validation (10 × 5-CV). In each of the five cross-
validation iterations, 80% of the data were first used as
input to the inner loop procedure for feature selection
and training the classifier with the selected features,
and finally, the remaining 20% of the data were used
to test the classifier. The 95% CI for the area under
the receiver operating characteristics curve (AUC) was
approximated by [AUC - 1.96 SEM, AUC + 1.96
SEM]. The SEM was estimated by averaging the 10
estimates of the standard error of the mean obtained
from the five different estimates of the AUC produced
by the 5-CV.
The second method in the outer loop is a bootstrap-
based method, also known as a smoothed version of
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cross-validation [20]. Efron and Tibshirani [20] proposed
the leave-one-out bootstrap method on the performance
metric error rate, and their technique was recently
extended by Yousef and colleagues [11] to the perfor-
mance metric AUC. This method uses a leave-pair-out
(LPO) bootstrap approach to estimate the mean AUC
(mean over training sets) and a “delta method after
bootstrap” to estimate the variability of the estimated
mean AUC. We point out that this variability captures
both the effect of finite training-set size and the effect
of finite testing-set size. In the LPO approach, multiple
(n = 5,000) training sets are obtained by stratified boot-
strap resampling, and each training set is used as input
to the inner-loop procedure for feature selection and
training the classifier with the selected features. In test-
ing, any pair of cases (one from the positive class and
one from the negative class) is tested on the classifiers
trained on the bootstrap samples that do not contain
the two held-out cases. The Wilcoxon-Mann-Whitney
statistic of the prediction results on pairs of cases is
averaged over all bootstrap-training sets and is used to
estimate the mean AUC. An advantage of this technique
is that it allows estimating the variability of the AUC
estimator by using the influence function method
[11,20]. By assuming that the estimated AUC is asymp-
totically normal, the 95% CI of the AUC can be approxi-
mated by [AUC - 1.96 SEM; AUC + 1.96 SEM].
The estimated performance and the associated CIs
from the training and internal-assessment process are
compared with the independent validation performance.
The conditional validation performance was obtained by
selecting features and training the classifier with the
training data set and testing on the validation data set.
This performance is conditional on the particular finite
training set and may vary when the training set varies.
Therefore, we estimated the mean of this conditional
performance where the mean is over multiple training
sets and obtained by bootstrapping the training set mul-
tiple times and averaging the conditional AUCs, as
tested on the validation set [21].
We also estimated the variability of the conditional
validation performance and decomposed the variance
into two components: the variability due to the finite
size of the training set and the variability due to the
finite size of the test set [21]. The training variability
reflects the stability of the classifier performance when
the training set varies, and the testing variability reflects
the expected performance variation for different test
sets.
To compare the ability of the performance estimates
of 10 × 5-CV and the LPO bootstrap to predict the per-
formance on the independent set, we used a root mean
square error (RMSE) measure, which is defined as
RMSE A AF C
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where F and C index feature selection and classifier,
respectively, A denotes the mean AUC; the superscript
“internal” can be “10 × 5-CV” or “LPO bootstrap.”
Estimation of predictor learning over increasing training-
set size
Predictor learning was evaluated for the models that
performed nominally the best in independent valida-
tion for each of the three prediction problems. All 230
cases were included in the analysis to fit learning
curves to these three models. For the ER-status end-
point, 10 different training-sample sizes, ranging from
n = 60 to n = 220 by increments of 20, were used to
estimate the dependence of the performance para-
meters on the sample size. For each sample size, 10
different random samples were drawn from the full set
by stratified sampling, and fivefold cross-validation was
used to assess the error rate and AUC of the models
where all the parameters of the models were recalcu-
lated. A similar approach was taken for the pCR (n =
50, 70, ..., 210) and “pCR in ER-negative cancer” pre-
dictors (n = 25, 40, ..., 85). By following the work of
Fukunaga [22], the following learning-curve model was
fit to the resulting AUC: Y = a+b/TrainingSize.
Congruence of different predictors at gene and functional
pathway level
We were interested in examining the congruence of
informative features that were selected by different
methods for the same prediction endpoint and also for
different endpoints. Both gene-level and pathway-level
analyses were performed as described previously [23].
MetaCore protein-function classification was used to
group genes into protein functions, and GeneGo Path-
way maps were used for functional classification of
predictive features. We assessed congruency by using
the kappa statistics. The input for kappa involves “lear-
ners” that classify a set of objects into categories. We
considered each feature-selection method as a learner
and each probe set as an object. The probe sets used
in this analysis are presented in Additional file 4. Each
probe set from the rank-ordered lists is categorized by
each feature-selection method either as 1 (that is,
selected as informative) or 0 (that is, nonselected). By
using such an 0/1 matrix for all probe sets × all fea-
ture-selection methods for every prediction endpoint
as input, we can calculate Cohen ’s kappa function
for the congruency. For pathway-level analysis, we
mapped the probe sets to pathway lists by using
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hypergeometric enrichment analysis. The pathways are
ranked by enrichment P values, and the top n path-
ways (n equals the number of genes in the input list
for comparison and consistency between the two
levels) were selected for presentation.
All statistical analysis was performed by using R
software.
Results
Difficulty of the classification problems
Three distinct classification problems were studied: (a)
ER-status prediction, including 80 ER-positive (62%) and
50 ER-negative training cases (38%); (b) pCR prediction,
including 33 cases with pCR (25%) and 97 cases with
residual cancer (75%) for training; and (c) pCR prediction
for ER-negative cancers, including 27 training cases with
pCR (54%) and 23 with residual cancer (46%). Figure 1
shows the cumulative information scores for the three
endpoints: larger cumulative information is an indicator
for a simpler classification problem. The obtained rank-
ing implies that the three endpoints represent different
degrees of classification difficulty.
We also assessed the significance of the utility scores by
using permutation tests (10,000 permutations) for com-
puting the raw P values, followed by Benjamini-Hochberg
correction for multiple testing. For the ER-status end-
point, 1,502 features with significant utility scores (P
value < 0.0001) were used, whereas for the pCR (all
cases), 252 significant features and only five features (cor-
responding to A2M [HGNC:7], RNMT [HGNC:10075],
KIAA0460 [HGNC:29039], AHNAK [HGNC:347], and
ACSM1 [HGNC:18049] genes) were used for pCR among
ER-negative cancers.
Effect of feature-selection methods and classification
algorithms on cross-validation performance
Figure 2 illustrates the average cross-validation AUC
estimated by 10 × 5-CV for all predictors, stratified by
feature-selection method (left column). All feature-selec-
tion methods performed similarly in combination with
various classification algorithms for a given endpoint.
The two non-t test-based methods, FS4 and FS5,
showed slightly better performances than did t test-
based feature selection for the most difficult prediction
Figure 1 Relative complexity of the three prediction problems. The cumulative information values have been scaled such that the
maximum value is 1. To make the curves comparable and to take into account the sample size, the ratio between the number of features used
in the cumulative information (F) and the sample size is used on the horizontal axis. Larger values of the cumulative information indicate simpler
problems.
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endpoint “pCR on ER-negative cancers” in cross valida-
tion, but confidence intervals widely overlapped. Addi-
tional file 5 shows the average error rates and AUCs
generated from 10 × 5-CV for each prediction model
applied to all three classification problems, along with
the average number of features selected. Interestingly,
the number of selected features did not increase as the
prediction problem became more difficult. For the most
difficult problem, the number of selected features was
lower than that for the moderately difficult problem.
This is probably because of the lack of informative fea-
tures: as the classification problem becomes more diffi-
cult, fewer features are informative for the outcome
(also see Figure 1).
Figure 2 also shows the variability of the classification
error rates and AUC estimated through 10 × 5-CV for
all predictors, stratified by classification algorithm (right
column). All methods performed similarly. The predic-
tion endpoint (that is, classification difficulty) had the
greatest effect on the cross-validation AUC. The effects
of feature-selection method and choice of classifier algo-
rithm were modest.
Bootstrap and independent-validation results
Figure 3 shows the estimated AUCs obtained with 10 ×
5-CV (black square), LPO bootstrap (black circle), and
the conditional AUC (blue circle) on the independent
validation set and its variability (blue error bar repre-
senting ± 2 SD) and mean (red cross). Additional file 5
includes the internal (10 × 5-CV and LPO bootstrap)
and independent validation-performance metrics for
each predictor. Both internal-estimation methods
yielded AUCs that were very close, well within 2 stan-
dard deviations of the mean, to the conditional and
mean AUCs observed in the independent validation.
Internal-performance estimates generated within the
training set only slightly overestimated the performance
relative to independent validation, indicating both that
the modeling approach was correct and that no strong
batch effect occurred between training and validation
sets. Simpler linear methods, such as LREG, LDA, and
DLDA, performed generally well in both internal and
independent validation, and these methods were among
the top five nominally best-performing models for all
prediction endpoints [see Additional file 5]. The non-t
test-based feature-selection methods (FS4, FS5) that
showed good results in cross validation also performed
well in independent validation and were included in
four of the top five models for each endpoint. However,
the 95% CIs of the point estimates overlap broadly for
all predictors, and no single strategy emerged as clearly
superior for any particular endpoint.
To assess the confidence-interval estimation, we calcu-
lated the RMSE for the AUC estimates obtained with 10
× 5-CV and LPO bootstrap for all the three endpoints.
Leave-pair-out bootstrap performed better than 10 × 5-
CV in terms of the agreement with the mean AUC esti-
mated in the independent-validation set: RMSEs for
LPO bootstrap were 0.0484, 0.0491, and 0.357 in com-
parison with 0.0562, 0.0713, and 0.449 for 10 × 5-CV
for the ER status, pCR, and pCR within ER-negative
endpoints, respectively.
Figure 3 clearly shows that the variability of the esti-
mated classification performance increases as the level
of classification difficulty increases. This implies that,
to achieve the same level of statistical precision of the
estimated performance, more cases are needed for a
more-difficult endpoint. Figure 3 also shows both the
conditional (blue circle) and mean validation AUCs
(red cross). The larger the difference between the con-
ditional validation AUC and the mean validation AUC,
the less stable the predictor is with respect to varying
the training sets. A quantitative measure of classifier
stability is the training variability, and we have decom-
posed the variability of the conditional validation AUC
shown in Figure 3 into two components (training
variability and testing variability) and put the results in
Additional file 5.
Predictor-performance and sample-size estimations
through learning curves
To estimate the training-set size that is necessary to
develop predictors that operate near their respective pla-
teaus, we examined how the performance characteristics
of each of the nominally best predictors for each end-
point improved as the training-set size increased. For
ER-status prediction, we selected QDA with FS1 (condi-
tional validation AUC = 0.939); for pCR prediction
including both the ER-positive and -negative cancers, we
selected LREG with FS5 (conditional validation AUC =
0.805); and for pCR in ER-negative cancers, we selected
LREG with FS4 (conditional validation AUC = 0.627).
Figure 4 shows the observed changes in average AUCs
for each of the classifiers as the training-set size
increased from 60 to 220 (or from 25 to 85 for pCR pre-
diction in ER-negative cancers) and the projected
improvements for assumed larger training sets. The
results indicate that for the easiest problem (ER), the
predictor seems to perform at its best with a sample
size around 80 to 100. For the moderately difficult pro-
blem (pCR), the steady increase of the learning curve
suggests that the performance of the model can be
improved by increasing the sample size, beyond the
highest value currently tested (220). For the pCR in ER-
negative cancer endpoint, the learning curves manifested
a very modest and gradual improvement in performance
between training sample sizes of 25 and 85, suggesting
that either too few samples were available for a reliable
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estimation of the learning curve or that limited informa-
tion in the mRNA space exists to predict this particular
outcome with the methods applied in this analysis. The
learning curve that had a slope significantly different
from 0 was the one for the pCR endpoint (P = 0.001;
ER endpoint, P = 0.05; pCR in ER-negative endpoint, P
= 0.365).
Functional analysis of predictive features
Our results demonstrate that several different feature
sets can yield predictors with statistically similar
performances [8-10,24]. This may occur because the
various probe sets that represent different genes capture
information from the same complex molecular pathways
that determine a particular clinical outcome [25]. In
other words, different features measure different compo-
nents of the same informative biologic pathway. To test
this concept, we mapped each of the 15 feature sets
used in the final validation models to known biologic
pathways. The different feature sets selected for a parti-
cular prediction endpoint had a high level of congruency
at both the gene and the pathway levels across all the
Figure 2 Boxplots of the estimated area under the curve (AUC), stratified by feature-selection and classification methods. The boxplots
show the mean AUC in 10 times fivefold cross validation (CV). The left column contains the estimated AUC stratified by the feature-selection
method, and the right column contains the estimated AUC stratified by the classification method.
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five different ranking methods (Table 2). The selected
gene sets and pathways were also rather similar to each
other for the ER and pCR prediction endpoints. How-
ever, the genes and pathways predictive of pCR in ER-
negative cancers were very different from the other two
informative gene sets.
Additional file 6 contains the pathway-enrichment
tables for the three endpoints, including pathways with
enrichment P values < 0.1. Thirty-two pathways contrib-
uted to the prediction of ER status; 36, to pCR predic-
tion; and 11, to pCR prediction within ER-negative
cancers across the five feature-selection methods. For
the ER endpoint, development, cell adhesion, cytoskele-
ton remodeling, DNA damage, apoptosis, and ER tran-
scription factor activity were the most significant
pathway elements common to all informative feature
sets. We also noted that most pathways that were
involved in pCR prediction (31 of 36) were the same as
those involved in ER-status prediction. This is consis-
tent with the known association between pCR rate and
ER status [7]. Estrogen receptor-negative cancers had
significantly higher pCR rates than ER-positive cancers
0.2
0.4
0.6
0.8
1
ER status
0.2
0.4
0.6
0.8
1
0.2
0.4
0.6
0.8
1
A
UC
0.2
0.4
0.6
0.8
1
0.2
0.4
0.6
0.8
1
D
LD
A
LD
A
K
N
N
3
K
N
N
11
SV
M
05
SV
M
2
LR
EG QD
A
pCR
D
LD
A
LD
A
K
N
N
3
K
N
N
11
SV
M
05
SV
M
2
LR
EG QD
A
FS
1
pCR|ER−
FS
2
FS
3
FS
4
D
LD
A
LD
A
K
N
N
3
K
N
N
11
SV
M
05
SV
M
2
LR
EG QD
A
FS
5
 
 
10x5−CV (± 2SD)
LPO bootstrap (± 2SD)
conditional indep. valid. (± 2SD)
mean of indep. valid.
chance line
Figure 3 Graphic summaries of the estimated and observed areas under the curve (AUCs) for each of the 120 models. For each
combination of feature-selection method and classification algorithm, the AUCs ± 2 standard deviations are plotted. Mean AUCs obtained from
10 × 5-CV (cross-validation; black square), LPO bootstrap (black dot), and the conditional (blue circle) and mean (red cross) validation AUCs are
shown.
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(54% pCR in ER-negative cancers versus 7.5% pCR in
ER-positive cancers; c2 test P value = 1.068e-08). The
pathways that were selected for prediction of pCR in
ER-negative cancers were distinct from the pathways
that were predictive of pCR in all patients and included
immune response-related pathways (IL-2 and T-helper
cell activation), opioid-receptor signaling, and endothe-
lial cell-related pathways.
Discussion
The goal of this analysis was to examine how the choice
of a univariate feature-selection method and classifica-
tion algorithm may influence the performance of predic-
tors under varying degrees of classification difficulty.
We examined the influence of changing two critical
components, feature selection and classification algo-
rithm in the predictor development process, for three
different prediction problems that represented three
levels of difficulty in a clinically annotated human breast
cancer data set. Classification of breast cancer into ER-
positive or -negative categories is an easy classification
problem; the large number of informative probe sets
and high information content of the features allow clear
separation of the groups. The AUC values for the 40
different prediction models for this endpoint ranged
from 0.875 to 0.939 in the independent validation set.
Prediction of pCR across all breast cancers, including
both ER-negative and ER-positive cases, represented a
slightly more difficult prediction problem with AUCs
ranging between 0.61 and 0.80 in the validation set. Pre-
diction of pCR in the molecularly more homogeneous
ER-negative breast cancer subpopulaton proved to be
the most difficult classification challenge: the validation
AUCs ranged from 0.34 to 0.62. No predictor-develop-
ment strategy emerged as clearly superior for any of the
classification problems. The 95% CI of the prediction
accuracies overlaped broadly for most of the predictors.
However, LDA, DLDA, LREG, and QDA classification
algorithms were consistently among the best-performing
models for each problem. Interestingly, KNN3 and SVM
methods were often among the worst-performing mod-
els in independent validation, even though these reached
relatively high AUC values in cross validation. It is pos-
sible that further fine tuning of parameters for these
Figure 4 Learning curves for the best predictors for each of the three endpoints. For each endpoint, the learning curve of the best-
performing model on the validation set was estimated by fivefold cross-validation for gradually increasing sample sizes. The plot shows both
the estimated performance for different sample sizes and the fitted curve. The quadratic discriminant analysis (QDA) classifier required more than
60 samples, so the minimum sample size for it was 80. Note the nonlinear scale of the x-axis.
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more-complex classifiers (in the sense of an implemen-
table decision boundary) could have improved predictive
performance. We examined only the radial function ker-
nel for SVM with two a priori set kernel parameters g =
0.5 and 2.0, and the parameter C (cost of misclassifica-
tion) was also fixed at 10. Fixing these parameters may
have resulted in “less than optimally trained” models
that could lead to added variability in the performance
of the classifiers. Also, we examined only two versions
of KNN with a priori set k of 3 and 11, and found that
KNN11 outperformed KNN3. Low values of k yield
local classifiers with low bias but high variance, whereas
higher values led to more-global classifiers with higher
bias and lower variance; exploring a broader range of k
values could have optimized prediction results. Optimiz-
ing the parameters g or k is not a straightforward task.
It should be done within the inner cross-validation pro-
cess, just as is done with feature selection. Fine tuning
different model parameters outside of the two-stage
cross-validation process would lead to model-selection
bias, or optimization bias [19].
An interesting observation was that simple feature-
selection methods that ranked features based on
difference in means performed very well in both
cross-validation and independent validation relative to
the more commonly used t statistic-based ranking.
Four of the top five models for each prediction pro-
blem used features selected by the non-t test-based
methods. However, it is important to recognize that
all of the feature-selection methods that we examined
represented univariate filtering approaches that rank
features individually and independent of the classifica-
tion method. It is possible that nonparametric or
multivariate feature-selection methods could yield dif-
ferent results. Penalized feature-selection methods,
which embed feature selection in the classifier fitting
step, may also have advantages, because features that
might not be discriminatory individually could be
jointly predictive in combination with other features.
At least one article suggested that multivariate sparse
penalized likelihood methods, including lasso and
elastic net, might have a slight edge compared with
univariate filtering [26]. Other publications that com-
pared several univariate and multivariate feature-
selection methods in public cancer data sets by using
10-fold cross-validation estimates found that simple
univariate feature-selection methods often outper-
formed more-complex multivariate approaches
[27,28].
Our data demonstrate that many different feature sets
and classification methods can yield similarly accurate
predictors for a given endpoint. When we mapped the
feature sets generated by five different univariate fea-
ture-selection methods to biologic pathways, each
method tended to identify similar genes and pathways.
The biologic pathways that were implicated in ER-status
or pCR prediction were distinct from the pathways that
were predictive of pCR in ER-negative cancers. This
pathway-level analysis is hypothesis generating and will
require further laboratory validation to determine the
importance of the identified pathways (for example,
immune response, endothelial-cell regulation, G-protein
signaling) in the biology of chemotherapy response in
ER-negative breast cancer.
To estimate potential improvements in predictive per-
formance of the nominally best predictors for each clas-
sification problem, we pooled all cases and carried out a
series of split-sample training and validation analyses in
which the predictors were trained on increasingly larger
data sets. For the easy classification problem (ER-status),
relatively small sample sizes (80 to 100 samples) were
enough for constructing excellent predictors. In con-
trast, for the moderately difficult problem (pCR predic-
tion), the accuracy of the model steadily improved as
the sample size increased. For the most difficult pro-
blem, pCR prediction in ER-negative cancer, a minimal
improvement was observed over a range of 25 to 85
training cases. It is important to note that the pCR and
ER status predictors trained on 80 cases showed good
or excellent conditional AUCs (0.65 and 0.94, respec-
tively). This modest performance and limited improve-
ment of the pCR predictor for ER-negative cancer may
be due to (a) too small sample size for trainig or (b) the
incompletness of the mRNA expression-based feature
space, meaning that this class-separation problem can-
not be fully accomplished by using information only
from the available probes by using the methods that we
applied. However, fitting learning curves to preliminary
data sets could assisst investigators in estimating
Table 2 Congruencies across different endpoints and
different feature-selection methods
Same endpoint but different feature selection (FS)
Endpoint Gene-level Level of canonic-pathway maps
ER status 0.541 0.573
pCR 0.544 0.572
pCR(ER-) 0.593 0.532
Same FS but different endpoints
FS Gene-level Level of canonic-pathway maps
FS1 0.300 0.290
FS2 0.299 0.274
FS3 0.291 0.278
FS4 0.295 0.291
FS5 0.272 0.282
The table shows that kappa statistics (that is, congruency) are high for
different feature-selection methods for the same endpoint but are low for the
same feature-ranking method for different endpoints. Both gene-level and
pathway-level analyses show similar results.
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sample-size requirements for a particular prediction pro-
blem for any given model.
Conclusions
This analysis confirms that it is possible to build multi-
gene classifiers of clinical outcome that hold up in inde-
pendent validation. Predictor performance is determined
largely by an interplay between training-sample size and
classification difficulty. Variations on univariate feature-
selection methods and choice of classification algorithm
had only a modest impact on predictor performance,
and it is clear that within our statistical precision, sev-
eral equally good predictors can be developed for each
of our classification problems. Pathway-level analysis of
informative features selected by different methods
revealed a high level of congruency. This indicates that
similar biologic pathways were identified as informative
for a given prediction endpoint by the different univari-
ate feature-selection methods. The independent valida-
tion results also showed that internal 10 × 5-CV and
LPO bootstrap both yielded reasonably good and only
slightly optimistic performance estimates for all the
endpoints.
Additional file 1: Supplemental Table S1. Clinical data for all the
patients in the training and validation sets.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2468-S1.xls ]
Additional file 2: Supplemental Table S2. Quality control results.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2468-S2.xls ]
Additional file 3: Supplemental Table S3. Pathways mapping for all
endpoints.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2468-S3.xls ]
Additional file 4: Supplemental methods. Pseudo-code description of
the two-level external cross-validation scheme.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2468-S4.pdf ]
Additional file 5: Supplemental Table S4. Features (probesets) selected
in the 120 models.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2468-S5.xls ]
Additional file 6: Supplemental Table S5. Estimated and validation
performance of all models.
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